Abstract
PROLONGED anticoagulant therapy of thromboembolic disease with coumarin and related drugs has become increasingly common in recent years and has heightened awareness of the shortcomings of the Quick one-stage prothrombin-time method for controlling dosage of the drug. Development of the one-stage prothrombin-time procedure made long-term anticoagulation possible. However, it has been the experience here and elsewhere1 that a major or minor bleeding episode may develop in many patients on long-term therapy, occasionally while the prothrombin time is in the therapeutic range. This range for the one-stage method is generally taken to be a patient's value one and a half to . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
